- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05076175
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
May 26, 2026 updated by: Bristol-Myers Squibb
A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission.
Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Recruiting
- The Children's Hospital at Westmead
-
Contact:
- Shoma Dutt, Site 0094
- Phone Number: 0298453999
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Recruiting
- Monash Health
-
Contact:
- Edward Giles, Site 0085
- Phone Number: +61395943577
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Withdrawn
- Local Institution - 0086
-
-
-
-
-
Brussels, Belgium, 1090
- Completed
- Local Institution - 0056
-
Edegem, Belgium, 2650
- Not yet recruiting
- Local Institution - 0063
-
Contact:
- Site 0063
-
Liège, Belgium, 4000
- Recruiting
- Centre Hospitalier Régional de la Citadelle
-
Contact:
- Emeline Bequet, Site 0061
- Phone Number: 32 4321 54 67
-
Liège, Belgium, 4000
- Withdrawn
- Local Institution - 0071
-
-
Bruxelles-Capitale, Région de
-
Brussels, Bruxelles-Capitale, Région de, Belgium, 1090
- Withdrawn
- Local Institution - 0076
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- Recruiting
- UZ Leuven
-
Contact:
- Ilse Hoffman, Site 0059
- Phone Number: 003216343343
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Withdrawn
- Local Institution - 0083
-
Toronto, Ontario, Canada, M5G 1X8
- Not yet recruiting
- Local Institution - 0082
-
Contact:
- Site 0082
-
Toronto, Ontario, Canada, M3M 0B2
- Not yet recruiting
- Local Institution - 0104
-
Contact:
- Site 0104
-
-
-
-
-
Bron, France, 69500
- Recruiting
- Hospices Civils de Lyon - Hopital Femme Mère Enfant
-
Contact:
- Remi Duclaux-Loras, Site 0022
- Phone Number: 0472357050
-
Caen, France, 14033
- Recruiting
- Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre
-
Contact:
- Claire Dupont-Lucas, Site 0030
- Phone Number: 33668354806
-
Paris, France, 75015
- Recruiting
- Hôpital Universitaire Necker Enfants Malades
-
Contact:
- Frank Ruemmele, Site 0017
- Phone Number: 0615781674
-
Paris, France, 75571
- Withdrawn
- Local Institution - 0073
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, France, 31059
- Recruiting
- CHU de Toulouse - Hôpital des Enfants
-
Contact:
- EMMANUEL MAS, Site 0058
- Phone Number: 0685946782
-
-
-
-
-
Dresden, Germany, 01307
- Recruiting
- Universitaetsklinikum Carl Gustav Carus Dresden
-
Contact:
- Martin Laass, Site 0031
- Phone Number: 00493514583449
-
-
Bavaria
-
München, Bavaria, Germany, 80337
- Completed
- Local Institution - 0032
-
-
Saxony
-
Leipzig, Saxony, Germany, 04103
- Recruiting
- Universitätsklinikum Leipzig
-
Contact:
- Gunter Flemming, Site 0097
- Phone Number: +49-341-9726111
-
-
-
-
Central District
-
Petah Tikva, Central District, Israel, 49202
- Recruiting
- Schneider Children's Medical Center
-
Contact:
- Dror Shouval, Site 0020
- Phone Number: 03-9253673
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 9013102
- Recruiting
- Shaare Zedek Medical Center
-
Contact:
- Dan Turner, Site 0019
- Phone Number: 02-6666482
-
-
Northern District
-
Haifa, Northern District, Israel, 3109601
- Recruiting
- Rambam Health Care Campus
-
Contact:
- Ron Shaoul, Site 0018
- Phone Number: 04-7774381
-
-
-
-
-
Hiroshima, Japan, 734-8551
- Recruiting
- Hiroshima University Hospital
-
Contact:
- Shiro Oka, Site 0069
-
Tokyo, Japan, 113-8431
- Recruiting
- Juntendo University Hospital
-
Contact:
- Takahiro Kudo, Site 0010
- Phone Number: +81-3-3813-3111
-
-
Aichi-ken
-
Ōbu, Aichi-ken, Japan, 474-8710
- Recruiting
- Aichi Children's Health and Medical Center
-
Contact:
- Naomi Iwata, Site 0025
- Phone Number: 81562430500
-
-
Fukuoka
-
Kurume-shi, Fukuoka, Japan, 8300011
- Recruiting
- Kurume University Hospital
-
Contact:
- Tatsuki Mizuochi, Site 0011
- Phone Number: +81-942-35-3311
-
-
Ishikawa-ken
-
Komatsu, Ishikawa-ken, Japan, 923-8560
- Recruiting
- Komatsu Municipal Hospital
-
Contact:
- HISASHI KANEDA, Site 0068
- Phone Number: 81-761-22-7111
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 2300012
- Recruiting
- Saiseikai Yokohamashi Tobu Hospital
-
Contact:
- shuichiro umetsu, Site 0038
- Phone Number: +81455763000
-
-
Osaka
-
Takatsuki, Osaka, Japan, 569-8686
- Recruiting
- Osaka Medical and Pharmaceutical University Hospital
-
Contact:
- Emiri Kaji, Site 0021
- Phone Number: 81-726-83-1221
-
-
Tokyo
-
Bunkyo-Ku, Tokyo, Japan, 113-8519
- Recruiting
- Institute of Science Tokyo Hospital
-
Contact:
- Toshimitsu Fujii, Site 0024
- Phone Number: +81-3-5803-5877
-
Setagaya-ku, Tokyo, Japan, 1578535
- Recruiting
- National Center for Child Health and Development
-
Contact:
- Katsuhiro Arai, Site 0009
- Phone Number: +81-3-3416-0181
-
Shinjuku-ku, Tokyo, Japan, 160-0023
- Recruiting
- Tokyo Medical University Hospital
-
Contact:
- Shigeo Nishimata, Site 0033
- Phone Number: 81333426111
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Poland, 30-663
- Withdrawn
- Local Institution - 0084
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Poland, 50-369
- Recruiting
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
-
Contact:
- Tomasz Pytrus, Site 0012
- Phone Number: +48 71 7703045
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Poland, 00-728
- Recruiting
- WIP Warsaw IBD Point Profesor Kierkus
-
Contact:
- Monika Meglicka, Site 0043
- Phone Number: +48603508908
-
Warsaw, Masovian Voivodeship, Poland, 04-746
- Recruiting
- Centrum Zdrowia Dziecka w Warszawie
-
Contact:
- Jaroslaw Kierkus, Site 0014
- Phone Number: +48500111648
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Poland, 35-302
- Withdrawn
- Local Institution - 0015
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Poland, 80-803
- Withdrawn
- Local Institution - 0013
-
Gdansk, Pomeranian Voivodeship, Poland, 80-803
- Withdrawn
- Local Institution - 0079
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Poland, 71-434
- Recruiting
- Twoja Przychodnia SCM
-
Contact:
- Beata Gawdis-Wojnarska, Site 0088
- Phone Number: +48664929399
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Poland, 91-738
- Completed
- Local Institution - 0092
-
-
-
-
-
San Juan, Puerto Rico, 00909-1711
- Recruiting
- Clinical Research Puerto Rico
-
Contact:
- Antonio Del Valle-Segarra, Site 0098
- Phone Number: 787-723-5945
-
-
-
-
-
Moscow, Russia, 119991
- Withdrawn
- Local Institution
-
Moskva, Russia, 119571
- Withdrawn
- Local Institution
-
-
-
-
-
Madrid, Spain, 28046
- Withdrawn
- Local Institution - 0050
-
Madrid, Spain, 28007
- Completed
- Local Institution - 0057
-
-
Barcelona [Barcelona]
-
Badalona, Barcelona [Barcelona], Spain, 08916
- Completed
- Local Institution - 0048
-
Esplugues de Llobregat, Barcelona [Barcelona], Spain, 08950
- Completed
- Local Institution - 0051
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spain, 28009
- Completed
- Local Institution - 0044
-
-
-
-
England
-
Birmingham, England, United Kingdom, B4 6NH
- Recruiting
- Birmingham Children's Hospital
-
Contact:
- Rafeeq Muhammed, Site 0054
- Phone Number: 07788861236
-
-
Greater London
-
London, Greater London, United Kingdom, SE5 9RS
- Recruiting
- King's College Hospital
-
Contact:
- Babu Vadamalayan, Site 0026
- Phone Number: 02032991674
-
London, Greater London, United Kingdom, SW10 9NH
- Not yet recruiting
- Local Institution - 0105
-
Contact:
- Site 0105
-
-
London, City of
-
London, London, City of, United Kingdom, E1 1BB
- Recruiting
- Barts Health NHS Trust
-
Contact:
- Protima Deb, Site 0066
- Phone Number: 02035942473
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85016-7710
- Withdrawn
- Local Institution - 0041
-
Tucson, Arizona, United States, 85724
- Withdrawn
- University of Arizona
-
-
California
-
Garden Grove, California, United States, 92845
- Completed
- Local Institution - 0052
-
Loma Linda, California, United States, 92354
- Recruiting
- Loma Linda University Health System
-
Contact:
- Kalyan Ray Parashette, Site 0087
- Phone Number: 505-274-0704
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Medical Center
-
Contact:
- Shervin Rabizadeh, Site 0074
- Phone Number: 310-423-7100
-
Palo Alto, California, United States, 94304
- Not yet recruiting
- Lucile Packard Children's Hospital
-
Contact:
- Jonathan Moses, Site 0080
- Phone Number: 650-721-2250
-
Sacramento, California, United States, 95817
- Recruiting
- University of California Davis Health
-
Contact:
- Trinh Truong, Site 0096
- Phone Number: 310-597-1251
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Completed
- Local Institution - 0007
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20010
- Completed
- Local Institution - 0064
-
-
Florida
-
Orlando, Florida, United States, 32803
- Completed
- Local Institution - 0075
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Completed
- Local Institution - 0016
-
-
Illinois
-
Park Ridge, Illinois, United States, 60068
- Not yet recruiting
- Local Institution - 0101
-
Contact:
- Site 0101
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Not yet recruiting
- Local Institution - 0100
-
Contact:
- Site 0100
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Completed
- Local Institution - 0049
-
-
Maine
-
Portland, Maine, United States, 04102
- Not yet recruiting
- Maine Medical Partners
-
Contact:
- Noah Hoffman, Site 0090
- Phone Number: 207-662-5522
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Contact:
- Athos Bousvaros, Site 0005
- Phone Number: 617-699-1021
-
Springfield, Massachusetts, United States, 01199
- Completed
- Local Institution - 0042
-
Worcester, Massachusetts, United States, 01655
- Recruiting
- University of Massachusetts Chan Medical School
-
Contact:
- Basavaraj Kerur, Site 0095
- Phone Number: 774-441-8082
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Completed
- Local Institution - 0093
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester, Minnesota
-
Contact:
- Michael Stephens, Site 0070
- Phone Number: 111111
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Recruiting
- Washington University
-
Contact:
- Charles Samson, Site 0053
- Phone Number: 513-518-8949
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center
-
Contact:
- JOSEPH PICORARO, Site 0040
- Phone Number: 212-305-5903
-
New York, New York, United States, 10065
- Withdrawn
- Local Institution - 0023
-
New York, New York, United States, 10029
- Completed
- Local Institution - 0028
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Withdrawn
- University of North Carolina Medical Center
-
Charlotte, North Carolina, United States, 28203
- Completed
- Local Institution - 0047
-
-
Ohio
-
Cleveland, Ohio, United States, 44124
- Recruiting
- Cleveland Clinic
-
Contact:
- Jessica Barry, Site 0036
- Phone Number: 216444231
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Withdrawn
- Local Institution - 0062
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Completed
- Local Institution - 0045
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Not yet recruiting
- Local Institution - 0099
-
Contact:
- Site 0099
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Not yet recruiting
- Local Institution - 0103
-
Contact:
- Site 0103
-
Houston, Texas, United States, 77030
- Recruiting
- Texas Children's Hospital
-
Contact:
- Lina Karam, Site 0067
- Phone Number: 832-822-3612
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Contact:
- Ghassan Wahbeh, Site 0060
- Phone Number: 111111
-
Seattle, Washington, United States, 98122
- Completed
- Local Institution - 0091
-
Tacoma, Washington, United States, 98405
- Recruiting
- Multicare Health System
-
Contact:
- Raghu Varier, Site 0046
- Phone Number: 503-847-4748
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Completed
- Local Institution - 0037
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
- Moderately to severely active Ulcerative Colitis (UC) diagnosed prior to the Screening Visit
- Evidence of UC extending beyond the rectum, as determined by baseline endoscopy
- Has had an inadequate response, loss of response to, or is intolerant to at least 1 of the following treatments for UC: oral aminosalicylates, systemic corticosteroids, immunomodulators, biologic therapy
Exclusion Criteria
- Diagnosis of Crohn's disease or indeterminate colitis
- Has documentation of positive test for toxin producing Clostridium difficile, or polymerase chain reaction examination of the stool
- Apheresis within 2 weeks of randomization
- History of or currently active primary or secondary immunodeficiency, or participants with known genetic disorders as a cause for colitis
- Other protocol-defined inclusion/exclusion criteria apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Ozanimod High Dose
|
Specified dose on specified days
Other Names:
|
|
Experimental: Ozanimod Low Dose
|
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of participants who achieve clinical remission
Time Frame: At Week 52
|
At Week 52
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of participants who achieve clinical remission
Time Frame: At Week 10
|
At Week 10
|
|
Proportion of participants who achieve clinical response
Time Frame: At Week 52
|
At Week 52
|
|
Proportion of participants who achieve clinical response
Time Frame: At Week 10
|
At Week 10
|
|
Proportion of participants who achieve symptomatic remission
Time Frame: At Week 10 and Week 52
|
At Week 10 and Week 52
|
|
Time to achievement of symptomatic remission
Time Frame: Up to 6 years
|
Up to 6 years
|
|
Proportion of participants who achieve endoscopic improvement
Time Frame: At Week 10 and Week 52
|
At Week 10 and Week 52
|
|
Proportion of participants who achieve corticosteroid free remission
Time Frame: At Week 52
|
At Week 52
|
|
Incidence of Adverse Events (AEs)
Time Frame: Up to 6 years
|
Up to 6 years
|
|
Incidence of Serious Adverse Events
Time Frame: Up to 6 years
|
Up to 6 years
|
|
Incidence of AEs leading to discontinuation from treatment
Time Frame: Up to 6 years
|
Up to 6 years
|
|
Incidence of AEs of special interest (AESIs)
Time Frame: Up to 6 years
|
Up to 6 years
|
|
Steady state systemic exposure of ozanimod and CC112273
Time Frame: At Week 18 and throughout the study, up to 70 weeks
|
At Week 18 and throughout the study, up to 70 weeks
|
|
Absolute change from baseline in Absolute Lymphocyte Count (ALC)
Time Frame: Up to 6 years
|
Up to 6 years
|
|
Percent change from baseline in ALC
Time Frame: Up to 6 years
|
Up to 6 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 30, 2022
Primary Completion (Estimated)
May 22, 2026
Study Completion (Estimated)
August 14, 2031
Study Registration Dates
First Submitted
October 4, 2021
First Submitted That Met QC Criteria
October 4, 2021
First Posted (Actual)
October 13, 2021
Study Record Updates
Last Update Posted (Actual)
May 27, 2026
Last Update Submitted That Met QC Criteria
May 26, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Intestinal Diseases
- Digestive System Diseases
- Gastrointestinal Diseases
- Colonic Diseases
- Gastroenteritis
- Inflammatory Bowel Diseases
- Colitis
- Colitis, Ulcerative
- Sphingosine 1 Phosphate Receptor Modulators
- Immunosuppressive Agents
- Immunologic Factors
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- ozanimod
Other Study ID Numbers
- IM047-001
- 2023-509248-86 (Other Identifier: EU CTR)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD Sharing Time Frame
See Plan Description
IPD Sharing Access Criteria
See Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colitis, Ulcerative
-
Odyssey TherapeuticsRecruitingUlcerative Colitis (UC) | UC - Ulcerative ColitisAustralia, Austria, Jordan, Poland, Ukraine, New Zealand, Canada, Czechia, Lithuania, Moldova
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; MRSU 938 - Research Center of Saint...Not yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncActive, not recruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
InventisBio Co., LtdRecruitingModerately to Severely Active Ulcerative Colitis | UC - Ulcerative ColitisChina
-
Dr Abdurrahman Yurtaslan Ankara Oncology Training...CompletedDisease Activity | Ulcerative Colitis Flare | Remission of Ulcerative ColitisTurkey
-
Eli Lilly and CompanyRecruitingUlcerative Colitis, Active Severe | Ulcerative Colitis (UC) | Ulcerative Colitis, Active ModerateUnited States, China, Croatia, France, India, Japan, Israel, Taiwan, Brazil, Serbia, Greece, Hungary, Argentina, Italy, Poland, Czechia, Colombia, Lithuania, Latvia, Ukraine, South Africa, Portugal, Mexico, Canada, Slovakia, Turkey (Türkiye) and more
-
Merck Sharp & Dohme LLCRecruitingUlcerative Colitis | Colitis UlcerativeUnited States
Clinical Trials on Ozanimod
-
CelgeneTerminatedCrohn DiseaseUnited States, Germany, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Georgia, India, Israel, Italy, Latvia, Mexico, Poland, Romania, Saudi Arabia, S... and more
-
CelgeneCompletedHealthy VolunteersUnited States
-
CelgeneTerminatedCrohn DiseaseUnited States, Australia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Lithuania, Netherlands, Poland, Portugal, Senegal, Serbia, Slovakia, Slovenia, South Africa, Spain and more
-
Bristol-Myers SquibbRecruitingMultiple Sclerosis, Relapsing-RemittingUnited States, Taiwan, Spain, Australia, Italy, Portugal, Mexico, Poland, Turkey (Türkiye), Puerto Rico, Romania
-
CelgeneCompletedUlcerative ColitisUnited States, Czechia, Germany, Greece, Romania, Ukraine, Belgium, Slovakia, Bulgaria, United Kingdom, Australia, Belarus, Hungary, Canada, Croatia, Israel, Italy, Moldova, Poland, South Korea
-
Bristol-Myers SquibbRecruitingUlcerative Colitis (UC)Japan
-
CelgeneCompleted
-
CelgeneTerminatedCrohn DiseaseUnited States, Australia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Lithuania, Netherlands, Poland, Portugal, Senegal, Serbia, Slovakia, Slovenia, South Africa, Spain and more
-
I.R.C.C.S. Fondazione Santa LuciaTerminated
-
University of Colorado, DenverRecruitingRelapsing Multiple SclerosisUnited States